| IPO Date | February 20, 2026 to February 24, 2026 |
| Listing Date | February 27, 2026 |
| Face Value | ₹ 5 / Share |
| Price Band | ₹ 75 to ₹ 79 / Share |
| Lot Size | 189 Shares |
| Total Issue Size | 2,08,86,200 (Aggregating up to ₹165 Cr) |
| Fresh Issue | 1,13,92,500 (Aggregating up to ₹90 Cr) |
| Offer for Sale | 94,93,700 (Aggregating up to ₹75 Cr) |
| Employee Discount | |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 6,13,94,384 |
| Share holding post issue | 7,27,86,884 |
| Market Maker portion |
Gaudium IVF IPO opens on February 20, 2026, and closes on February 24, 2026.
| IPO Open Date | February 20, 2026 |
| IPO Close Date | February 24, 2026 |
| Basis of Allotment | February 25, 2026 |
| Initiation of Refunds | February 25, 2026 |
| Credit of Shares to Demat | February 26, 2026 |
| Listing Date | February 27, 2026 |
| Cut-off time for UPI mandate confirmation | February 24, 2026 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 189 | Rs.14,931 |
| Retail (Max) | 13 | 2,457 | Rs.194,103 |
| S-HNI (Min) | 14 | 2,646 | Rs.209,034 |
| S-HNI (Max) | 66 | 12,474 | Rs.985,446 |
| B-HNI (Min) | 67 | 12,663 | Rs.1,000,377 |
| HNI (Min) |
| Share Holding Pre Issue | 6,13,94,384 |
| Share Holding Post Issue | 7,27,86,884 |
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | |
|
| Market Maker Shares Offered | |
|
| Other Shares Offered | |
|
| QIB Shares Offered | Not more than 50% of the Net Offer |
|
| NII (HNI) Shares Offered | Not more than 15% of the Net Offer |
|
| bNII > ₹10L | |
|
| sNII < ₹10L | |
|
| Retail Shares Offered | Not less than 35% of the Net Offer |
|
| Employee Shares Offered | |
|
| Total Shares Offered | |
| Bid Date | |
| Shares Offered | |
| Anchor Portion Size (In Cr.) | |
| Anchor lock-in period end date for 50% shares (30 Days) | |
| Anchor lock-in period end date for remaining shares (90 Days) |
Founded in March 2015, Gaudium IVF is a prominent company that provides IVF treatments to ladies in India. With 28 spokes and seven hubs (centers), the corporation runs its operations across 30 locations. Patients from Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman are among the nations where the firm provides care.
Intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), ovulation induction, in vitro fertilization (IVF) are among the fertility services the company provides. Both sexes are the focus of its therapies. The company also offers endometriosis, PCOD/PCOS, and particular treatment for pregnant women with complicated fertility problems. Additionally, Gaudium IVF provides innovative sperm retrieval techniques as well as treatments for male infertility.
| KPI | Values |
|---|---|
| ROE | 41.31% |
| ROCE | 39.70% |
| Debt/Equity | 0.41 |
| RoNW | 41.71% |
| P/BV | 10.48 |
| PAT Margin (%) | 26.96% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 3.12 | 3.44 |
| P/E (x) | 25.36 | 22.99 |
Gaudium IVF & Women’s Health Ltd. B1/51, Janak Puri, New Delhi, New Delhi, 110058 Phone: 011-4885 8585 Email: [email protected] Website: https://www.gaudiumivfcentre.com/ |
Bigshare Services Pvt. Ltd. Phone: +91-22-6263 8200 Email: [email protected] |